Unichem Laboratories · NSE: UNICHEMLAB · BSE: 506690
Q2 FY26 results · Jul–Sep 2025
Unichem Laboratories reported revenue from operations of ₹578.96 crore (up 25.3% from Q2 FY25) and net loss of ₹11.89 crore for Q2 FY26 (Jul–Sep 2025), on a consolidated basis.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 578.96 | 462.16 | +25.3% | 526.60 | +9.9% |
| Other income | 20.97 | 8.79 | +138.6% | 6.82 | +207.5% |
| Total income | 599.93 | 470.95 | +27.4% | 533.42 | +12.5% |
| Profit before tax | (10.82) | 32.99 | Turned loss | (9.02) | Loss widened |
| Net profit for the period | (11.89) | 30.49 | Turned loss | (10.47) | Loss widened |
| EPS, basic (₹) | (1.69) | 4.34 | Turned loss | (1.49) | Loss widened |
| Net margin (%) | -2.1 | 6.6 | -2.0 |
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 356.90 | 436.88 | −18.3% | 384.25 | −7.1% |
| Other income | 21.40 | 7.08 | +202.3% | 4.25 | +403.5% |
| Total income | 378.30 | 443.96 | −14.8% | 388.50 | −2.6% |
| Profit before tax | (37.83) | 43.37 | Turned loss | (1.87) | Loss widened |
| Net profit for the period | (39.93) | 43.37 | Turned loss | (1.85) | Loss widened |
| EPS, basic (₹) | (5.67) | 6.16 | Turned loss | (0.26) | Loss widened |
| Net margin (%) | -11.2 | 9.9 | -0.5 |
Consolidated
- Filed with BSE
- 11 Nov 2025, 14:49 IST
- Board meeting
- 11 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 11 Nov 2025, 14:49 IST
- Board meeting
- 11 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE